Advanced Urothelial Carcinoma
Advertisement
Drs. Gupta and Nizam discuss the findings from the patient-reported outcomes in the EV-302 trial for urothelial carcinoma.
The recorded ORR was 53.5%, and the disease control rate was 74.1%.
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
Dr. Grivas offers long-term outcomes from the JAVELIN Bladder 100 study pertaining to specific patient populations.
Dr. Grivas provides an update on relevant clinical trial updates and data readouts pertaining to urothelial carcinoma.
Drs. van der Heijden and Nizam weigh the EV-302 subanalyses of the cisplatin-eligible, -ineligible populations.
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
Trial data showed that patients who received the combination therapy experienced improved OS, PFS, and ORR.
NECTIN4 mRNA expression as a biomarker for EV therapy linked to better outcomes in advanced urothelial carcinoma.
An update on clinical efficacy and an exploratory biomarker analysis from the NABUCCO trial for patients with stage III UC.
In this study, Dr. Shilpa Gupta and colleagues examined patient-reported outcomes from the landmark EV-302 trial.
EV-302 trial: Enfortumab vedotin and pembrolizumab improve outcomes vs standard chemotherapy in advanced urothelial cancer.
Dr. van der Heijden presents a follow-up analysis of patients who were cisplatin-ineligible at randomization for EV-302.
Drs. Koshkin and Nizam discuss the trastuzumab deruxtecan FDA approval and the DESTINY-PanTumor02 clinical trial.
A retrospective analysis of ctDNA data by clinical outcomes with pembro vs chemotherapy for aUC from KEYNOTE-361.
Previous studies have demonstrated the efficacy of postchemotherapy nivolumab with high-dose ipilimumab for metastatic UC.
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Researchers found increased OS and PFS benefits when patients received nivolumab plus gemcitabine.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.